Effectiveness of BNT162b2 Vaccine Against Omicron-SARS-CoV-2 Subvariants in Children 5-11 Years of Age in Quebec, Canada, January 2022 to January 2023.

Harimahefa RazafimandimbyChantal SauvageauManale OuakkiSara CarazoDanuta M SkowronskiGaston De Serres

Published in: The Pediatric infectious disease journal (2023)

In children 5-11 years of age, VE against symptomatic infection was stable at any interval between doses but decreased with time since the last dose and against more divergent omicron subvariants.

Keyphrases

sars cov
young adults
randomized controlled trial
systematic review
coronavirus disease